JCNN News Summaries - Japan Corporate News Network - Sankyo to Launch Osteoporosis Treatment Drug in Europe
Osteoporosis Drug Protects Against Breast Cancer The osteoporosis drug raloxifene (Evista) may be just as effective as tamoxifen at reducing the risk of invasive breast cancer, according to results from the STAR clinical trial, which compared how well the two drugs prevent breast cancer in high-risk postmenopausal women.
Related Results
Raloxifene reduces the risk of breast cancer
News You Can Use
E-Vista Release 1.2. (Products).
Lilly offers help to needy seniors. (Supplier News).(Brief Article)
Breast Cancer; Prevention
The study found that raloxifene, a drug used to prevent and treat osteoporosis in postmenopausal women, reduced invasive breast cancer incidence by nearly half. “It’s good news for postmenopausal women who are at increased risk for breast cancer. It gives them a new option in the chemoprevention of breast cancer,” says D. Lawrence Wickerham, M.D., associate chairman of the National Surgical Adjuvant Breast and Bowel Project, the National Cancer Institute—funded group that conducted the study. Not only did raloxifene reduce the incidence of invasive breast cancer as effectively as tamoxifen, it was able to do so with fewer serious side effects, including …
Read the full article with a Free Trial at MyWire.
